Drug details:
Molecular formula: C₄₄H₅₂N₂O₁₆

Standard name: 3-[4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-N-[2-[2-[2-[[3-[4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]benzoyl]amino]ethoxy]ethoxy]ethyl]benzamide

Curated SMILES: C1=CC(=CC(=C1)C(=O)NCCOCCOCCNC(=O)C2=CC=CC(=C2)C3=CC=C(C=C3)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C5=CC=C(C=C5)O[C@@H]6[C@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O

Evidence for compound's anti-virulence activity:

Escherichia
Related VF: Type 1 fimbriae
Target: FimH
Drug effect: Bound to the FimH lectin domain to interfere with bacterial adhesion, invasion and biofilm formation.
Max phase: Preclinical (in vitro)
Publication:
Han Z, et al., 2010. Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem 53(12):4779-92.